December 15th, 2020
1:00 PM — 2:15 PM EST
There is no doubting the impact that 2020 has had on our industry, our country, and our world. With more than 700 therapeutics in the pipeline for COVID-19 alone, speed-to-clinic is a top priority for early-phase manufacturers. There are myriad considerations when transitioning from the lab to clinical operations, specifically for emerging industries such as cell and gene therapy and microbiome technologies. This talk illustrates the current industry challenges with early phase cGMP manufacturing and provides sustainable design alternatives to overcome such challenges.
Top Reasons to Attend:
- Understand current industry challenges around the transition from R&D through early phase clinical manufacturing
- Address the unique challenges with novel therapeutics such as Cell and Gene Therapy and Microbiome based therapies
- Compare of existing options versus Cleanrooms on Demand
- Define phase-appropriate cGMP and its effect on speed to clinic
- Case studies of this novel business model in action, by which a Boston-area therapeutics manufacturer leveraged on-demand cleanroom space to extend the runway of their early-phase manufacturing
